ghk-cu immunogenicity antibody formation risk Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins | BioDrugs Reducing Immunogenicity by Design: Approaches
Description
By simultaneously activating the GLP-1, GIP, and Glucagon receptors, this compound is currently the subject of intensive study regarding its potential impact on metabolic efficiency and energy regulation
Why was AOD 9604 development discontinued
It is considered safe under medical supervision.
Yellow, brown, or any color change signals degradation
[DOI] [PubMed] [Google Scholar] Hoffmans R, Stadeli R, Basler K
